I’m not sure your looking at it the right way. I

I’m not sure your looking at it the right way. If they truly have mostly all Critical patients and were only at 25% death rate I would take taht as all great news. Especially given the fact that all patients as far as I know we’re able to continue on SOC in addition to either getting leronlimab or Placebo. I feel real bad for the ones who only hit SOC because none of those have had a tdouble blinded trial showing any improvement in mortality yet we have seen statistical significance in our phase 2 m/m news score and 60+ % in reduction of SAE. Plus we have been successful in saving many of the most critical patients. Not everyone obviously but the patients that were lost were very early on April or so when hospitals were behind the 8 ball. I’m making educated guess that we reduce mortality by 50+ percent and Steven Hahn head of FDA is quoted 35% reduction is a dream Number for plasma and that statistic wasn’t Even proven in a double blinded placebo or at all for that matter. So if we are around 22-23 death and we have double the patients because of 2-1 trail set up that would be about 50% reduction. Or 17% in leronlimab side and 35% in placebo side. Unmet need in pandemic FDA has stated looking at risk benefit and Leronlimab so safe that there is only benefit by taking the drug it’s why the FDA approved 60+ eind and we were embarrassing Bog Pharma because no one else was getting the results we were. Congrats shareholders were almost there turning the final corner with a HUGE lead.